
Sign up to save your podcasts
Or


Antimicrobial resistance is getting worse. Set to impact healthcare, agriculture and insurance, it’s a phenomenon worth paying attention to. On this episode, we take a look at whether there’s an investment case for fighting back against the superbugs.
Host: Bentley Kaplan, MSCI ESG Research
Guest: Namita Nair, MSCI ESG Research
By MSCI ESG Research LLC4.8
134134 ratings
Antimicrobial resistance is getting worse. Set to impact healthcare, agriculture and insurance, it’s a phenomenon worth paying attention to. On this episode, we take a look at whether there’s an investment case for fighting back against the superbugs.
Host: Bentley Kaplan, MSCI ESG Research
Guest: Namita Nair, MSCI ESG Research

956 Listeners

304 Listeners

1,248 Listeners

399 Listeners

496 Listeners

639 Listeners

128 Listeners

228 Listeners

466 Listeners

102 Listeners

60 Listeners

77 Listeners

177 Listeners

267 Listeners

229 Listeners